Accessing_VBG
Epstein-Barr_JJ
virus-specific_JJ
T-cell_NN
memory_NN
with_IN
peptide-loaded_JJ
dendritic_JJ
cells_NNS
._.

The_DT
conventional_JJ
means_NN
of_IN
studying_VBG
Epstein-Barr_JJ
virus_NN
-LRB-_-LRB-
EBV_NN
-RRB-_-RRB-
-_:
induced_JJ
cytotoxic_JJ
T-lymphocyte_NN
-LRB-_-LRB-
CTL_NN
-RRB-_-RRB-
memory_NN
,_,
by_IN
in_FW
vitro_FW
stimulation_NN
with_IN
the_DT
latently_RB
infected_VBN
autologous_JJ
lymphoblastoid_JJ
cell_NN
line_NN
-LRB-_-LRB-
LCL_NN
-RRB-_-RRB-
,_,
has_VBZ
important_JJ
limitations_NNS
._.

First_RB
,_,
it_PRP
gives_VBZ
no_DT
information_NN
on_IN
memory_NN
to_TO
lytic_JJ
cycle_NN
antigens_NNS
;_:
second_RB
,_,
it_PRP
preferentially_RB
amplifies_VBZ
the_DT
dominant_JJ
components_NNS
of_IN
latent_JJ
antigen-specific_JJ
memory_NN
at_IN
the_DT
expense_NN
of_IN
key_JJ
subdominant_JJ
reactivities_NNS
._.

Here_RB
we_PRP
describe_VBP
an_DT
alternative_JJ
approach_NN
,_,
based_VBN
on_IN
in_FW
vitro_FW
stimulation_NN
with_IN
epitope_NN
peptide-loaded_JJ
dendritic_JJ
cells_NNS
-LRB-_-LRB-
DCs_NNS
-RRB-_-RRB-
,_,
which_WDT
allows_VBZ
one_CD
to_TO
probe_VB
the_DT
CTL_NN
repertoire_NN
for_IN
any_DT
individual_JJ
reactivity_NN
of_IN
choice_NN
;_:
this_DT
method_NN
proved_VBD
significantly_RB
more_RBR
efficient_JJ
than_IN
stimulation_NN
with_IN
peptide_NN
alone_RB
._.

Using_VBG
this_DT
approach_NN
we_PRP
first_RB
show_VBP
that_IN
reactivities_NNS
to_TO
the_DT
immunodominant_JJ
and_CC
subdominant_JJ
lytic_JJ
cycle_NN
epitopes_NNS
identified_VBN
by_IN
T_NN
cells_NNS
during_IN
primary_JJ
EBV_NN
infection_NN
are_VBP
regularly_RB
detectable_JJ
in_IN
the_DT
CTL_NN
memory_NN
of_IN
virus_NN
carriers_NNS
;_:
this_DT
implies_VBZ
that_IN
in_IN
such_JJ
carriers_NNS
chronic_JJ
virus_NN
replication_NN
remains_VBZ
under_IN
direct_JJ
T-cell_NN
control_NN
._.

We_PRP
further_RB
show_VBP
that_IN
subdominant_JJ
latent_JJ
cycle_NN
reactivities_NNS
to_TO
epitopes_NNS
in_IN
the_DT
latent_JJ
membrane_NN
protein_NN
LMP2_NN
,_,
though_IN
rarely_RB
undetectable_JJ
in_IN
LCL-stimulated_JJ
populations_NNS
,_,
can_MD
be_VB
reactivated_VBN
by_IN
DC_NN
stimulation_NN
and_CC
selectively_RB
expanded_VBN
as_IN
polyclonal_JJ
CTL_NN
lines_NNS
;_:
the_DT
adoptive_JJ
transfer_NN
of_IN
such_JJ
preparations_NNS
may_MD
be_VB
of_IN
value_NN
in_IN
targeting_VBG
certain_JJ
EBV-positive_JJ
malignancies_NNS
._.

